Listenly

What is the actual cost of innovation in pharmaceutical development and how does competition affect pricing once drugs are established?

Answered at 8:55 in Healthcare Fixed: No Insurance Needed, Same Doctors, 60% Less - David Goldhill · Proven Podcast

— questions searchable right now

What is the actual cost of innovation in pharmaceutical development and how does competition affect pricing once drugs are established?

The first drug to reach market costs $9 million because it must fund all research, clinical studies, and regulatory approval —but once that single pill is approved, the second pill costs only a penny to manufacture. Yet prices remain artificially high because insurance structures eliminate direct price competition between suppliers and patients.

This gap between innovation cost and production cost reveals the core problem in pharmaceutical pricing. The entire burden of funding research and development falls on the first approved drug. Once a company recovers that investment and moves to mass production, the marginal cost per unit becomes negligible.

The real barrier to lower prices, however, is how insurance intermediaries control the relationship between patients and drug makers. When insurers decide coverage, patients have no direct bargaining power. This eliminates the one force that typically drives prices down in any market: competition for customers based on price.

When patients pay directly, prices fall without insurance

The real-world proof came from GLP-1 weight loss drugs. Prices for these medications declined significantly over the last three years despite zero insurance coverage. Companies like Novo Nordisk and Eli Lilly competed directly for direct-pay customers, forcing them to lower prices to remain competitive.

This mirrors what David Goldhill describes as a structural truth: in healthcare systems where insurers act as middle-men, nobody in the system can profit by lowering prices. Providers cannot attract more patients by cutting costs because insurers control patient volume. Insurers have no reason to demand lower prices because patients don't see the bill. The only way to break this cycle is to remove the third-party payment layer entirely.

David Goldhill on Proven PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

The first drug to reach market costs $9 million because it must fund all research, clinical studies, and regulatory approval —but once that single pill is approved, the second pill costs only a penny to manufacture.

David Goldhill · Healthcare Fixed: No Insurance Needed, Same Doctors, 60% Less - David Goldhill · Proven Podcast · answer at 8:55

Key takeaways

  • Yet prices remain artificially high because insurance structures eliminate direct price competition between suppliers and patients.
  • This gap between innovation cost and production cost reveals the core problem in pharmaceutical pricing.
  • The real barrier to lower prices, however, is how insurance intermediaries control the relationship between patients and drug makers.
  • The real-world proof came from GLP-1 weight loss drugs.
  • This mirrors what David Goldhill describes as a structural truth: in healthcare systems where insurers act as middle-men, nobody in the system can profit by lowering prices.

The full answer · about 11 min

The first drug to reach market costs $9 million because it must fund all research, clinical studies, and regulatory approval —but once that single pill is approved, the second pill costs only a penny to manufacture. Yet prices remain artificially high because insurance structures eliminate direct price competition between suppliers and patients.

This gap between innovation cost and production cost reveals the core problem in pharmaceutical pricing. The entire burden of funding research and development falls on the first approved drug. Once a company recovers that investment and moves to mass production, the marginal cost per unit becomes negligible.

The real barrier to lower prices, however, is how insurance intermediaries control the relationship between patients and drug makers. When insurers decide coverage, patients have no direct bargaining power. This eliminates the one force that typically drives prices down in any market: competition for customers based on price.

When patients pay directly, prices fall without insurance

The real-world proof came from GLP-1 weight loss drugs. Prices for these medications declined significantly over the last three years despite zero insurance coverage. Companies like Novo Nordisk and Eli Lilly competed directly for direct-pay customers, forcing them to lower prices to remain competitive.

This mirrors what David Goldhill describes as a structural truth: in healthcare systems where insurers act as middle-men, nobody in the system can profit by lowering prices. Providers cannot attract more patients by cutting costs because insurers control patient volume. Insurers have no reason to demand lower prices because patients don't see the bill. The only way to break this cycle is to remove the third-party payment layer entirely.

More answers from this episode

 ·  All answers from Proven Podcast →
—
—
0:00
0:00